![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis Gene Therapy for Vision Loss Approved in EU
Novartis Gene Therapy for Vision Loss Approved in EU
![Novartis logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/Novartis.gif?t=1631046727&width=430)
The European Commission cleared Novartis’ Luxturna (voretigene neparvovec) for treatment of vision loss due to a genetic mutation in both copies of the RPE65 gene.
The treatment delivers a normal copy of the gene to retinal cells to restore vision using a modified version of a naturally-occurring adeno-associated virus.
The European Commission based its approval on a Phase 3 clinical trial showing vision improvement as early as 30 days following treatment. Vision improved for 90 percent of trial subjects.
Upcoming Events
-
21Oct